RecruitingPhase 1NCT03533816

Expanded/Activated Gamma Delta T-cell Infusion Following Hematopoietic Stem Cell Transplantation and Post-transplant Cyclophosphamide

Studying Myeloid/lymphoid neoplasm associated with FGFR1 rearrangement

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
University of Kansas Medical Center
Principal Investigator
Joseph McGuirk, M.D.
University of Kansas Medical Center
Intervention
EAGD T-cell infusion (Phase I)(drug)
Enrollment
38 enrolled
Eligibility
18-65 years · All sexes
Timeline
20202028

Study locations (2)

Collaborators

In8bio Inc.

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT03533816 on ClinicalTrials.gov

Other trials for Myeloid/lymphoid neoplasm associated with FGFR1 rearrangement

Additional recruiting or active studies for the same condition.

See all trials for Myeloid/lymphoid neoplasm associated with FGFR1 rearrangement

← Back to all trials